Phibro Animal Health Corporation (Nasdaq: PAHC) announced financial results for its first quarter ended September 30, 2026 and maintained its financial guidance for the year ending June 30, 2027.
Highlights for the three months ended September 30, 2026 (compared to the three months ended September 30, 2025)
-
Net sales of $386.8 million, an increase of $22.9 million, or 6%
-
Net income of $29.5 million, an increase of $3.0 million, or 11%
-
Diluted income per share of $0.72, an increase of $0.07, or 11%
-
Adjusted EBITDA of $64.3 million, an increase of $2.4 million, or 4%
-
Adjusted net income of $32.4 million, an increase of $2.5 million, or 9%
-
Adjusted diluted EPS of $0.79, an increase of $0.06, or 8%
Phibro Animal Health Corporation reaffirmed its full-year financial guidance for fiscal year 2027 (ending June 30, 2027) following its Q1 FY2027 financial release.
The company continues to capitalize on the integration of its Medicated Feed Additives (MFA) portfolio while streamlining its manufacturing footprint and driving steady growth.
1. FY2027 Financial Guidance Summary
Metric |
FY2027 Guidance Range |
Midpoint / Target Growth |
FY2026 Reference |
Net Sales |
$1.55 Billion – $1.60 Billion |
~$1.575 Billion (+2% to +5%) |
$1.518 Billion |
Adjusted EBITDA |
$258 Million – $268 Million |
~$263 Million (+1% to +5%) |
$255.0 Million |
Adjusted Net Income |
$140 Million – $147 Million |
~$143.5 Million (+6% to +11%) |
$132.8 Million |
Adjusted Diluted EPS |
$3.41 – $3.59 |
~$3.50 (+4% to +9%) |
$3.25 |
Adjusted Effective Tax Rate |
~20.0% |
Down from ~23.7% in FY26 |
23.7% |
2. Segment Revenue & Operational Performance
A. Animal Health (Core Driver)
-
MFA & Other: Benefits from strong North American and Asian demand for medicated feed additives and ethanol processing aids. However, the FY2027 guidance conservatively assumes minimal contribution from virginiamycin sales in Brazil due to localized regulatory headwinds, providing potential upside if regulatory discussions resolve favorably.
-
Nutritional Specialties & Vaccines: Moderate growth expected across companion animal and North American swine markets, offset by macro headwinds in North American poultry and South American aquaculture.
B. Mineral Nutrition & Performance Products
-
Mineral Nutrition: Driven by sustained demand and favorable pricing for trace minerals, copper, and zinc oxide.
-
Performance Products: Modest growth tied to demand for specialized copper-based and fluoride products.
3. Strategic Restructuring & Capital Allocation Metrics
Network Optimization (Chicago Heights Facility Wind-down)
-
Footprint Restructuring: As part of its post-MFA acquisition review, Phibro is closing its manufacturing plant in Chicago Heights, Illinois, with operations scheduled to cease in the summer/early fall of 2027.
-
Impact & Efficiency: Affects ~100 employees; production is being systematically transferred to other Phibro-owned plants and select contract manufacturing organizations (CMOs) to optimize long-term gross margins and asset utilization.
-
Long-term Savings: Strategic supply chain consolidations are projected to deliver $15 million to $20 million in annualized cost savings, primarily materializing in FY2028 and beyond.
, adjusted EBITDA, leverage ratios){kind=link}